Stock News

aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan
aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
aTyr Pharma Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
Is aTyr Pharma (LIFE) A Good Stock To Buy Now?
aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update
aTyr Pharma Announces Publication in the Journal mAbs
aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2020 Financial Results - Management to host conference call and webcast on November 12th at 5:00 pm EST / 2:00 pm PST
aTyr Pharma Announces Research Collaboration with Medical University of South Carolina
aTyr Pharma to Participate in ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28th
aTyr Pharma Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
aTyr Pharma to Participate in October Virtual Investor Events
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Doses First Subjects in Phase 1 Trial of ATYR1923 in Japan
Virtual Conference for Life Sciences Companies Broadcast Live September 17th, 2020
aTyr Pharma Announces $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
aTyr Pharma to Present at September Investor Conferences

As seen on...